MANAMA, November 11 The National Health Regulatory Authority of the Kingdom of Bahrain (NHRA) today approved the emergency use of the COVID-19 vaccine, COVAXIN, produced by the Indian multinational biotechnology company, Bharat Biotech.
The inactivated COVAXIN vaccine has recently been approved by the World Health Organization and will be available in Bahrain for those 18 years of age and older.
The decision follows a careful evaluation of the data provided by the manufacturer, Bharath Biotech India, conducted by the NHRA’s Clinical Trials Committee and the Ministry of Health’s Immunization Committee.
More than 26,000 people have participated in clinical trials of the vaccine, which demonstrated that the two-dose regimen vaccine is 77.8% effective against COVID-19, and 93.4% effective against severe cases of COVID-19. Safety data indicated a low incidence of adverse effects.
NS